Investigating HIV in Children

Over the past 30 years, Gilead has led innovation that has helped transform HIV treatment options. The needs of children with HIV can be unique, we are committed to developing treatments with appropriate formulations to help advance options for children who are affected. A Gilead clinical trial may be an option in your child's treatment journey.


Featured Trials

Understanding Children with HIV

  • HIV in children is most commonly passed from mother to child during pregnancy, birth, or breast feeding. Adolescents may acquire it through sexual transmission.
  • Infants born to mothers with HIV are recommended to be tested for HIV as soon as possible, as early diagnosis is key.
  • Children with HIV without treatment tend to get sick more severely than HIV-negative children and adults, and have greater difficulty fighting common infections (e.g., ear and sinus infections, pneumonia, etc.)

Considerations for Developing Age Appropriate Treatments

Gilead's clinical trials seek to address specific needs for children

1 Easier to Take Formulations

Child appropriate formulations to be taken with liquids or food for children who may have difficulty swallowing.

2 Simplified Regimens

HIV treatments for children that minimize the number of tablets that they must take each day.

3 Better Tasting Medications

Treatments that have an acceptable taste for children to help with treatment adherence.


Confidentiality and Children in Clinical Trials

Disclosure of a child's HIV status can be a concern for parents and caregivers, and the stigma can make daily life feel isolating. A child's clinical trial participation is a personal decision made by the child's parents and/or caregivers, and uncertainty over confidentiality should not be a reason for concern. As with all medical records, participant privacy and confidentiality in trials are protected by law and regulations.

Community Outreach

Meet the people and programs dedicated to improving HIV research

Partnerships for a Healthier Future

Gilead is partnering with the Clinton Health Access Initiative (CHAI) and the Penta ID Network, a scientific organization dedicated to child health research, to accelerate the development, regulatory approval, and commercialization of a dispersible, fixed-dose combination treatment for children living with HIV.
penta logo

Designing HIV Medications Made for Children

One issue in HIV treatment for children is “adherence” of taking medication. Getting children to take medicine can be a challenge – the child may not like a medication’s bitter taste or may have trouble swallowing pills. A study of “bitter blockers” might help with the problem. 

Gilead is partnering with Monell Chemical Senses Center (Monell) and CHAI (Clinton Health Access Initiative) to identify bitter blockers for pediatric formulations of the medications TAF and SOF. Leveraging Monell’s deep knowledge of human taste biology, the study aims to identify better and pediatric-appropriate, fixed-dose combinations, reducing pill burden and promoting treatment adherence.
monell center logo

More Trials for HIV in Children

Explore Our Other HIV Research Areas

Your Questions Answered

We're working to discover, develop and deliver innovative therapeutics for people with life-threatening diseases.


We're working to discover, develop and deliver innovative therapeutics for people with life-threatening diseases.

All trials have different timelines due to various factors, such as the trial phase, study design, treatment duration or health condition being studied. During the consent process before enrolling, the research team will explain the specifics about the trial.
Due to the many differences in insurance plans across the country, coverage in clinical trials can vary. You will learn more about your options during pre-screening.
If you don’t qualify due to not meeting the trial criteria, you should check with your healthcare provider to seek other options.
If you are living with a medical condition, joining a clinical trial may give you access to a new potential treatment before it is publicly available. Just as importantly, it can help researchers understand how this potential treatment affects the body and increase their knowledge about the disease and how to treat it. Participation can also play a vital role in helping others who have a similar condition, both now and in the future. Healthy volunteers in trials contribute to this medical progress as well by helping understand the effect of the potential treatment and any safety concerns.
As with all medical records, participant privacy and confidentiality in trials are protected by law. Once consent is signed, you will be given a trial code. Your trial records will not include your name or personal identity but will identify you with a trial code. This code can only be tracked back to you via a code key which is held by the responsible physician. Your name or personal identity will never be disclosed.
Yes, participants are volunteers and may withdraw from a clinical trial at any time.
A placebo is an inactive version of an intervention that is not intended to provide any medical benefit. It is designed to look the same as the active intervention, so the participant and research team do not know it is a placebo. The placebo is used by comparison to confirm any effects of the intervention being studied, if no approved intervention is available.
"Standard of care" is an intervention already approved for a specific health condition that is available publicly. Interventions in a clinical trial are still being tested to ensure safety and effectiveness.
Some clinical trials are designed to be "double blind" so both participants and researchers are unaware of which treatment group participants are assigned to. This prevents bias from affecting clinical trial data.
Your informed consent is required before being enrolled in a trial. This means you have been provided all relevant information about the study design, how you will participate, your right to withdraw at any time, study alternatives, your personal data protection and the associated risks and benefits. Informed consent is designed to protect patient safety and privacy.
Under FDA regulations, an Institutional Review Board (IRB) is a group that has been formally designated to review and monitor research at a hospital or institution involving human participants. In accordance with FDA regulations, an IRB has the authority to approve, require modifications in, or disapprove research.
Participants are always welcome to visit their usual healthcare providers during a trial. Sometimes, it is important for healthcare providers to collaborate with the research team to ensure success.
After your participation ends, the study may continue for months or years. Once final results from all participants are compiled and analyzed, they are often published publicly. Clinical study report (CSR) synopses and plain language summaries (PLSs) may be made available for certain studies. Check with your clinical trial site or send an email to [email protected] to learn more.
There are a wide variety of professionals involved with any clinical trial, all of whom are vital to ensuring safety and success. The principal investigator, or PI, leads the trial and directs the team of doctors, nurses and other healthcare workers. The clinical trial coordinator manages day-to-day activities and is the main contact for participants. Many clinical trials also have an independent Data and Safety Monitoring Board (DSMB) who periodically reviews data to ensure participant safety, and sometimes effectiveness.